ENTITY
Kindstar Globalgene Technology

Kindstar Globalgene Technology (9960 HK)

12
Analysis
Health Care • China
Kindstar Globalgene Technology is a leading independent medical testing provider in China, specializing in esoteric diagnostic testing services. The company offers a wide range of advanced specialty testing across hematology, genetic diseases, rare diseases, infectious diseases, oncology, neurology, and maternity-related testing, alongside scientific research services and CRO. It was founded in 2003 and is headquartered in Wuhan, Hubei, China.
more
•04 May 2026 14:54•Primer

Primer: Kindstar Globalgene Technology (9960 HK) - May 2026

Kindstar Globalgene Technology is a premier independent provider of esoteric clinical testing services in China, specializing in complex...

Logo
αSK
99 Views
Share
bullish•ADICON
•18 Apr 2023 00:46

ADICON Holdings IPO: The Bull Case

The key elements of the bull case rest on the growing non-COVID-19 testing addressable market, improving market sentiment, strong non-COVID-19...

Logo
426 Views
Share
•15 Jul 2021 12:13

Kindstar (åŗ·åœ£ēŽÆēƒ) IPO Trading: Pattern of Demand Divergence

We look at the updates on Kindstar IPO since our last note. With its valuation higher than leading ICL peer, we do not expect a strong debut...

Logo
465 Views
Share
bullish•Full Truck Alliance
•04 Jul 2021 10:21

ECM Weekly (4th July 2021) - Xpeng, Medbot, Medlive, Brii Bio, CTOS, LinkDoc, Devyani, Manycore

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.

Share
•30 Jun 2021 03:19

Kindstar Globalgene IPO: Valuation Insights

At the mid-point of the IPO price range, the total net proceeds are HK$1,931.1 million ($250 million). Overall, we would participate in the IPO due...

Logo
580 Views
Share
x